GlassScriptPhysician profile
Lisa Stout
NPI 1548263213
$2,994.43
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,245 · 2020: $553 · 2021: $842 · 2022: $355.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $708.34 | 2019-2022 | |
| Astellas Pharma US INC | $514.85 | 2019-2022 | |
| Travere Therapeutics, INC. | $338.33 | 2019-2022 | |
| Duchesnay USA Incorporated | $233.18 | 2019 | |
| Allergan, INC. | $226.47 | 2019-2022 | |
| Janssen Biotech, INC. | $156.52 | 2019-2022 | |
| Ferring Pharmaceuticals INC. | $147.47 | 2019 | |
| Pfizer INC. | $115.44 | 2019-2020 | |
| Abbvie INC. | $56.88 | 2020-2022 | |
| Antares Pharma, INC. | $55.33 | 2021-2022 | |
| C. R. Bard, INC. & Subsidiaries | $51.18 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $47.36 | 2019-2020 | |
| Amgen INC. | $45.31 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $45.23 | 2019-2021 | |
| Dendreon Pharmaceuticals LLC | $36.67 | 2020-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $27.17 | 2019 | |
| Coloplast Corp | $25.39 | 2020-2022 | |
| Evofem Biosciences, INC. | $24.45 | 2021 | |
| Alnylam Pharmaceuticals INC. | $22.59 | 2021 | |
| Urovant Sciences INC | $18.09 | 2022 | |
| Photocure INC | $17.47 | 2020 | |
| Rochester Medical Corporation | $16.50 | 2019 | |
| Novartis Pharmaceuticals Corporation | $16.49 | 2020 | |
| Myriad Genetic Laboratories, INC. | $12.55 | 2021 | |
| Medtronic USA, INC. | $11.97 | 2019 | |
| Merck Sharp & Dohme LLC | $11.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.40 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Stout listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.